02.26.25 -- Where Are They Now? Tarsus Pharmaceuticals

Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. The Business of Biotech caught up with her at the JP Morgan Healthcare Conference in San Francisco for a discussion on Landmark's role in addressing the ATMP patient access and cost reduction challenges. Listen now and subscribe so you never miss an episode!

Numerous factors impact a drug safety program, but proper management of three key elements drives success while creating a scalable drug safety model.

By partnering with the ICLF, see how we were able to gain access to and build trust with influential community leaders and advocates within the African American communities located near study sites.

Review several actionable strategies to help ensure medical advancements benefit all populations through diverse representation in clinical trials.

Enrollment benchmarking, powered by advanced data solutions, has emerged as a critical tool in addressing patient enrollment challenges.

Explore critical considerations for biopharmaceutical developers and CDMOs during technology transfer as well as a successful transfer and scale-up of a cell line from a CLD platform to a global CDMO.